
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

Lobe Sciences Provides Update on L-130 Clinical Program
Details : The company’s lead clinical program, L-130 (psilocin Mucate), a proprietary stabilized conjugate drug candidate, 5-HT2A receptor agonist. It is being evaluating under Phase I clinical trial studies for the treatment of chronic cluster headaches.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Pharmaceutical Research Unit, Jordan
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate
Details : Psilocin is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : Psilocin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Pharmaceutical Research Unit, Jordan
Deal Size : Inapplicable
Deal Type : Inapplicable

Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
Details : L-130 (psilocin analogue), a proprietary stabilized psilocin analogue, which is invetigated for the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 27, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DHA
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Pentec Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD...
Product Name : Altemia
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : DHA
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Pentec Health
Deal Size : Undisclosed
Deal Type : Agreement

 Reset All
Reset All